Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/31723
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Çalapkulu, Murat | - |
dc.date.accessioned | 2023-03-23T13:40:50Z | - |
dc.date.available | 2023-03-23T13:40:50Z | - |
dc.date.issued | 2019-01-17 | - |
dc.identifier.citation | Çalapkulu, M. vd. (2019). ''Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center''. Diabetes & Metabolic Syndrome-Clinical Research & Reviews, 13(2), 1031-1034. | en_US |
dc.identifier.issn | 1871-4021 | - |
dc.identifier.issn | 1878-0334 | - |
dc.identifier.uri | https://doi.org/10.1016/j.dsx.2019.01.016 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1871402118306313 | - |
dc.identifier.uri | http://hdl.handle.net/11452/31723 | - |
dc.description.abstract | Introduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus which increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin (10 mg) on lipid profile were investigated retrospectively. Methods: A total of thirty-one type 2 diabetic patients with HbA1c level between 6,5% and 13%, aged 45 -80 years and whose body mass index higher than 20 kg/m(2) were enrolled to the study. Data before dapagliflozin treatment and three and six months results were recorded. Results: Dapagliflozin reduced HbA1c levels by 0,9% at 3 months and 0,79% at 6 months. Total cholesterol level decreased 17,6 mg/dl, LDL cholesterol level decreased 13,4 mg/dl and triglyceride level by 25.9mg/dl at the 6th months and it is observed that there is no serious side effect on the usage for 6 months. Conclusion: There are conflicting results about the effect of SGLT2 inhibitors on the lipid profile in the literature. According to our data, dapagliflozin has positive effects on lipid profile as weight and glycemic control and it is well tolerated. Therefore, dapagliflozin therapy is beneficial because of the positive change in lipid profile and weight loss in diabetic patients with overweight and hyperlipidemia. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Endocrinology & metabolism | en_US |
dc.subject | Type 2 diabetes | en_US |
dc.subject | Dapagliflozin | en_US |
dc.subject | Lipid profile | en_US |
dc.subject | Ldl | en_US |
dc.subject | Total cholesterol | en_US |
dc.subject | Triglyceride | en_US |
dc.subject | Glycemic control | en_US |
dc.subject | Therapy | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Benzhydryl compounds | en_US |
dc.subject.mesh | Biomarkers | en_US |
dc.subject.mesh | Blood glucose | en_US |
dc.subject.mesh | Diabetes mellitus, type 2 | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Follow-up studies | en_US |
dc.subject.mesh | Glucosides | en_US |
dc.subject.mesh | Glycated hemoglobin A | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lipids | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Retrospective studies | en_US |
dc.subject.mesh | Sodium-glucose transporter 2 inhibitors | en_US |
dc.title | Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center | en_US |
dc.type | Review | en_US |
dc.identifier.wos | 000466549300022 | tr_TR |
dc.identifier.scopus | 2-s2.0-85060310525 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri/İç Hastalıkları Bölümü. | tr_TR |
dc.identifier.startpage | 1031 | tr_TR |
dc.identifier.endpage | 1034 | tr_TR |
dc.identifier.volume | 13 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Diabetes & Metabolic Syndrome-Clinical Research & Reviews | en_US |
dc.contributor.buuauthor | Cander, Soner | - |
dc.contributor.buuauthor | Gül, Özen Öz | - |
dc.contributor.buuauthor | Ersoy, Canan | - |
dc.contributor.researcherid | AAI-1005-2021 | tr_TR |
dc.contributor.researcherid | AAH-8861-2021 | tr_TR |
dc.identifier.pubmed | 31336439 | tr_TR |
dc.subject.wos | Endocrinology & metabolism | en_US |
dc.indexed.wos | ESCI | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.contributor.scopusid | 25027068600 | tr_TR |
dc.contributor.scopusid | 26040787100 | tr_TR |
dc.contributor.scopusid | 6701485882 | tr_TR |
dc.subject.scopus | Antidiabetic Agent; Empagliflozin; Electron Microprobe Analysis | en_US |
dc.subject.emtree | Cholesterol | en_US |
dc.subject.emtree | Dapagliflozin | en_US |
dc.subject.emtree | Hemoglobin A1c | en_US |
dc.subject.emtree | Low density lipoprotein cholesterol | en_US |
dc.subject.emtree | Triacylglycerol | en_US |
dc.subject.emtree | 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol | en_US |
dc.subject.emtree | Venzhydryl derivative | en_US |
dc.subject.emtree | Biological marker | en_US |
dc.subject.emtree | Glucoside | en_US |
dc.subject.emtree | Glycosylated hemoglobin | en_US |
dc.subject.emtree | Hemoglobin A1c protein, human | en_US |
dc.subject.emtree | Lipid | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Body mass | en_US |
dc.subject.emtree | Body weight loss | en_US |
dc.subject.emtree | Cholesterol blood level | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Diabetic patient | en_US |
dc.subject.emtree | Drug effect | en_US |
dc.subject.emtree | Drug tolerability | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Glucose urine level | en_US |
dc.subject.emtree | Glycemic control | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hyperlipidemia | en_US |
dc.subject.emtree | Lipid analysis | en_US |
dc.subject.emtree | Low density lipoprotein cholesterol level | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Non insulin dependent diabetes mellitus | en_US |
dc.subject.emtree | Obesity | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Retrospective study | en_US |
dc.subject.emtree | Review | en_US |
dc.subject.emtree | Triacylglycerol level | en_US |
dc.subject.emtree | Blood | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Glucose blood level | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Non insulin dependent diabetes mellitus | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Very elderly | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.